Naturopathy & Integrative Medicine, Department of Gynecological Endocrinology and Reproductive Medicine, Women's Hospital, University of Heidelberg, Vosstrasse 9, Heidelberg, Germany.
Climacteric. 2012 Aug;15(4):358-67. doi: 10.3109/13697137.2011.597895. Epub 2011 Oct 23.
To evaluate the efficacy and safety of a complex remedy compared with placebo to treat menopausal symptoms.
A total of 102 peri- and postmenopausal women requiring treatment for menopausal symptoms were randomized to receive a complex anthroposophic remedy prepared in the homeopathic manner (Apis regina tota GL D4, Argentum metallicum D5, Ovaria bovis GL D4), 3 × 10 globuli daily (2 × 12 weeks) and placebo (12 weeks) in different orders of remedy (R) and placebo (P) (1: R/R/P, 2: P/R/R, 3: R/P/R). The primary endpoint was change in climacteric symptoms assessed by the Menopause Rating Scale II (MRS II) after 12 weeks. Secondary endpoints were changes of symptoms and safety throughout the study.
Reduction of symptoms after 12 weeks did not differ between remedy and placebo (total score MRS II: -1.4, 95% confidence interval (CI) -2.8 to 0 vs. -2.3, 95% CI -4.4 to -0.3, p = 0.441) and had no clinical relevance (defined as reduction in MRS II ≥ -3.5). Comparison of secondary outcomes at 12 weeks between remedy and placebo or between groups after the 2nd or 3rd period compared to previous periods did not differ. Treatment with remedy for 24 consecutive weeks did not reach clinical relevance either. However, total reduction of symptoms after three periods in Group 1 (R/R/P) (-5.0, 95% CI -7.5 to -2.5) and Group 2 (P/R/R) (-5.9, 95% CI -8.7 to -3.1) reached clinical relevance whereas almost no decrease of symptoms after three periods was seen in Group 3 (R/P/R) (-0.5, 95% CI -2.9 to 1.9).
Treatment with the complex remedy for 12 or 24 weeks did not result in clinically significant improvement of menopausal symptoms.
评估一种复方疗法与安慰剂治疗绝经症状的疗效和安全性。
共纳入 102 例绝经前后需要治疗绝经症状的女性,随机分为接受复方顺势疗法药物治疗组(Apis regina tota GL D4、Argentum metallicum D5、Ovaria bovis GL D4),每天 3×10 粒(12 周 2 次)和安慰剂(12 周),以不同的药物(R)和安慰剂(P)顺序(1:R/R/P、2:P/R/R、3:R/P/R)给药。主要终点是 12 周后用绝经评定量表 II(MRS II)评估的绝经期症状变化。次要终点是整个研究过程中症状和安全性的变化。
12 周后药物组和安慰剂组的症状缓解无差异(MRS II 总分:-1.4,95%置信区间(CI)-2.8 至 0 与 -2.3,95%CI-4.4 至 -0.3,p=0.441),且无临床意义(定义为 MRS II 减少≥-3.5)。与安慰剂或组间比较,12 周时次要结局的比较或第 2 或第 3 期与前几期比较无差异。连续 24 周用药物治疗也未达到临床意义。然而,第 1 组(R/R/P)(-5.0,95%CI-7.5 至-2.5)和第 2 组(P/R/R)(-5.9,95%CI-8.7 至-3.1)在 3 个周期后总症状缓解达到临床意义,而第 3 组(R/P/R)在 3 个周期后症状几乎无缓解(-0.5,95%CI-2.9 至 1.9)。
用该复方药物治疗 12 周或 24 周未显著改善绝经症状。